Company Overview of KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, primarily develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer in the United States. Its product candidates include KB001-A, which is in a Phase II clinical trial for the prevention and treatment of pseudomonas aeruginosa pneumonia and pseudomonas aeruginosa infection in cystic fibrosis patients; KB003 that is in a Phase II clinical trial for the treatment of severe asthma; and KB004, which is in a Phase I clinical trial for the treatment of hematologic malignancies and solid tumors. The company has a collaboration agreement with Sanofi Pasteur S.A. for the development of KB001-A; and an ag...
260 East Grand Avenue
South San Francisco, CA 94080
Founded in 2000
Key Executives for KaloBios Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $356.0K
Chief Scientific Officer and Executive Vice President of Research & Development
Total Annual Compensation: $275.0K
Chief Medical Officer
Total Annual Compensation: $208.2K
Compensation as of Fiscal Year 2012.
KaloBios Pharmaceuticals, Inc. Key Developments
KaloBios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013
Nov 12 13
KaloBios Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2013. The net loss for the third quarter of 2013 was $11.3 million, or $0.47 per basic and diluted share. This compared to a net loss of $8.6 million, or $4.05 per basic and diluted share, for the same period in 2012. The company reported contract revenue of $9,000, loss from operations of $11,087,000 against $69,000 and $8,291,000 respectively a year ago.
Net loss for the nine months ended September 30, 2013 was $31.7 million ($1.48 per basic and diluted share), compared to net loss of $11.8 million ($5.71 per basic and diluted share) for the nine months ended September 30, 2012. The company reported contract revenue of $40,000, loss from operations of $30,981,000 against $6,080,000 and $11,550,000 respectively a year ago.
KaloBios Pharmaceuticals, Inc. Receives U.S. Food & Drug Administration Approval for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
Oct 30 13
KaloBios Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has granted the company orphan drug designation for KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, for the treatment of cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). KaloBios is currently enrolling patients in a Phase 2 multiple-dose, randomized, double-blind, placebo-controlled clinical trial with KB001-A in CF patients chronically infected with Pa. This 180-patient study is intended to evaluate the efficacy and safety of repeat doses of KB001-A. The primary endpoint is time-to-need for antibiotics. Currently, KaloBios has three drug development programs: KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a Phase 2 study in the United States, Europe and Australia; KB001-A, an anti-PcrV mAb fragment that is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pa infections. KaloBios has retained rights for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios has received Orphan Drug designation from both the FDA and the European Commission for KB001-A for the treatment of Pa lung infection in CF. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation; KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.
KaloBios Pharmaceuticals, Inc. Announces Board Changes
Oct 23 13
On October 22, 2013, the Board of KaloBios Pharmaceuticals, Inc. appointed Laurie Smaldone Alsup, M.D. to serve as a director of the company, effective as of the close of business on October 22, 2013. The Board also appointed Dr. Smaldone Alsup to serve on the Compensation Committee of the Board, effective as of the close of business on October 22, 2013. Dr. Smaldone Alsup has served as President of PharmApprove, since August 2011. On October 23, 2013, the Company announced that Dennis Henner, Ph.D. resigned from his position as a director of the company, effective as of the close of business on October 22, 2013. Dr. Henner has stated that his resignation is not because of a disagreement with the company on any matter relating to the company's operations, policies or practices.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|